华兰生物：公司正加大对流感疫苗的市场供应

Core Viewpoint - The company, Hualan Biological Engineering, emphasizes its leading position in the domestic influenza vaccine market, highlighting increased demand for flu vaccinations and its commitment to meeting this demand through enhanced supply capabilities [1] Group 1: Company Overview - Hualan Biological's subsidiary, Hualan Vaccine, is the largest influenza vaccine producer in China, with an annual production capacity of 100 million doses [1] - Since the launch of the first quadrivalent influenza virus split vaccine in 2018, the company has maintained a strong market presence, consistently ranking among the top in production and sales [1] Group 2: Production and Sales - As of 2025, the company has issued a total of 54 batches of influenza vaccines, including 48 batches of the quadrivalent influenza virus split vaccine [1] - The company has observed a significant increase in public awareness regarding flu vaccinations, leading to a notable rise in demand orders from disease control centers compared to the same period last year [1] Group 3: Market Response - In response to the heightened demand, the company is increasing its market supply of influenza vaccines and is committed to timely distribution through its cold chain logistics system to meet vaccination needs across the country [1]